BR112015028174A2 - composto, composição farmacêutica, uso de uma composição farmacêutica, e, métodos para modulação de atividade de receptores de andrógeno e para aumentar a biodisponibilidade de um modulador de receptor de andrógeno - Google Patents

composto, composição farmacêutica, uso de uma composição farmacêutica, e, métodos para modulação de atividade de receptores de andrógeno e para aumentar a biodisponibilidade de um modulador de receptor de andrógeno

Info

Publication number
BR112015028174A2
BR112015028174A2 BR112015028174A BR112015028174A BR112015028174A2 BR 112015028174 A2 BR112015028174 A2 BR 112015028174A2 BR 112015028174 A BR112015028174 A BR 112015028174A BR 112015028174 A BR112015028174 A BR 112015028174A BR 112015028174 A2 BR112015028174 A2 BR 112015028174A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
androgen receptor
methods
compound
bioavailability
Prior art date
Application number
BR112015028174A
Other languages
English (en)
Portuguese (pt)
Inventor
Adriana Banuelos Carmen
Wang Jun
garcia fernandez Javier
Dorothy Sadar Marianne
R Mawji Nasrin
John ANDERSEN Raymond
Original Assignee
British Columbia Cancer Agency Branch
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51864937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015028174(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by British Columbia Cancer Agency Branch, Univ British Columbia filed Critical British Columbia Cancer Agency Branch
Publication of BR112015028174A2 publication Critical patent/BR112015028174A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/63—Halogen-containing esters of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/18—Acetic acid esters of trihydroxylic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112015028174A 2013-05-10 2014-05-09 composto, composição farmacêutica, uso de uma composição farmacêutica, e, métodos para modulação de atividade de receptores de andrógeno e para aumentar a biodisponibilidade de um modulador de receptor de andrógeno BR112015028174A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361822186P 2013-05-10 2013-05-10
PCT/CA2014/000414 WO2014179867A1 (en) 2013-05-10 2014-05-09 Ester derivatives of androgen receptor modulators and methods for their use

Publications (1)

Publication Number Publication Date
BR112015028174A2 true BR112015028174A2 (pt) 2017-07-25

Family

ID=51864937

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015028174A BR112015028174A2 (pt) 2013-05-10 2014-05-09 composto, composição farmacêutica, uso de uma composição farmacêutica, e, métodos para modulação de atividade de receptores de andrógeno e para aumentar a biodisponibilidade de um modulador de receptor de andrógeno

Country Status (17)

Country Link
US (2) US9173939B2 (https=)
EP (1) EP2994451A4 (https=)
JP (2) JP6100439B2 (https=)
KR (2) KR101739800B1 (https=)
CN (1) CN105358522A (https=)
AP (1) AP2015008838A0 (https=)
AU (2) AU2014262333B2 (https=)
BR (1) BR112015028174A2 (https=)
CA (1) CA2911352A1 (https=)
CL (1) CL2015003271A1 (https=)
HK (1) HK1221712A1 (https=)
IL (1) IL242345A (https=)
MX (1) MX347705B (https=)
PE (1) PE20160091A1 (https=)
PH (2) PH12015502525A1 (https=)
SG (2) SG10201607177XA (https=)
WO (1) WO2014179867A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2572596C2 (ru) 2008-07-02 2016-01-20 Бритиш Коламбиа Кэнсер Эйдженси Бранч Терапевтические средства на основе производных диглицилиловых простых эфиров и способы их применения
AR079846A1 (es) 2010-01-06 2012-02-22 British Columbia Cancer Agency Agentes terapeuticos derivados de bisfenol que contienen un grupo aquiral y su uso en el tratamiento del cancer
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
CN105358522A (zh) 2013-05-10 2016-02-24 不列颠哥伦比亚癌症局分支机构 雄激素受体调节剂的酯衍生物及其使用方法
SG11201601431VA (en) 2013-09-09 2016-03-30 British Columbia Cancer Agency Halogenated compounds for cancer imaging and treatment and methods for their use
JP6884100B2 (ja) * 2015-01-13 2021-06-09 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ がんの画像化及び治療用のヘテロ環式化合物ならびにそれらの使用方法
US10471023B2 (en) * 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
CA2929345A1 (en) * 2015-09-02 2017-03-02 British Columbia Cancer Agency Branch Co-targeting androgen receptor splice variants and mtor signaling pathway for the treatment of castration-resistant prostate cancer
US20170298033A1 (en) * 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2018045450A1 (en) * 2016-09-09 2018-03-15 British Columbia Cancer Agency Branch Bisphenol a compounds and methods for treating drug-resistant androgen receptor mediated cancers
US10933059B2 (en) * 2016-12-16 2021-03-02 Kangpu Biopharmaceuticals. Ltd. Combination, application thereof and treatment method
WO2018157232A1 (en) * 2017-02-28 2018-09-07 British Columbia Cancer Agency Branch Pharmaceutical compositions 'and combinations comprising inhibitors of the androgen receptor a1wd uses thereof
WO2019226991A1 (en) * 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
MX2021004427A (es) 2018-10-18 2021-11-12 Univ British Columbia Moduladores del receptor de andrógenos y métodos para su uso.
WO2020198712A1 (en) * 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
AU2021255723A1 (en) 2020-04-17 2022-12-08 Essa Pharma, Inc. Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof
CN113666806A (zh) * 2020-05-15 2021-11-19 上海安谱实验科技股份有限公司 一种双酚f 2,3-二羟丙基(2-氯-1-丙基)乙醚的制备方法
WO2023046283A1 (en) 2021-09-22 2023-03-30 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Compounds and their use in a method for modulating ar (androgen receptor) transcriptional activity
CN121652089A (zh) * 2024-09-11 2026-03-13 中国海洋大学 一种ntd抑制剂及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2571217A (en) 1951-10-16 Horace s
US4284574A (en) 1979-06-15 1981-08-18 Ciba-Geigy Corporation Diglycidyl ethers of di-secondary alcohols, their preparation, and curable compositions containing them
US4369298A (en) 1980-05-27 1983-01-18 Tokuyama Soda Kabushiki Kaisha Novel cured resin, process for production thereof, and lens composed of said resin from bis(alkyleneoxyphenyl)-diacrylate, bis(alkyleneoxyphenyl)diallyl ether, bis(alkyleneoxyphenyl)diallyl carbonate monomers
EP0056175B1 (en) 1981-01-13 1985-05-02 Teijin Limited Ion-permeable composite membrane and its use in selective separation
PL135932B2 (en) 1983-11-04 1986-01-31 Politechnika Warszawska Process for manufacturing polyfunctional polyols
US5753730A (en) 1986-12-15 1998-05-19 Mitsui Toatsu Chemicals, Inc. Plastic lenses having a high-refractive index, process for the preparation thereof and casting polymerization process for preparing sulfur-containing urethane resin lens and lens prepared thereby
DE3852839T2 (de) 1987-04-27 1995-06-22 Mitsubishi Gas Chemical Co Hitzehärtbare Harzzusammensetzung.
WO1988009782A1 (en) 1987-06-01 1988-12-15 The Dow Chemical Company Process for making propargyl ethers of hydroxyaromatic compounds
US5155196A (en) 1987-06-01 1992-10-13 The Dow Chemical Company Polymer resulting from the cure of a preformed chromene-containing mixture
DE3821585A1 (de) 1987-09-13 1989-03-23 Hoechst Ag Positiv arbeitendes strahlungsempfindliches gemisch und daraus hergestelltes strahlungsempfindliches aufzeichnungsmaterial fuer hochenergetische strahlung
US4855184A (en) 1988-02-02 1989-08-08 Minnesota Mining And Manufacturing Company Radiation-curable protective coating composition
DE3939760A1 (de) 1989-12-01 1991-06-06 Bayer Ag Verfahren zur lackierung von kunststoffen, lackierte kunststoffe und die verwendung von hierzu geeigneten haftvermittlern
EP0515128A1 (en) 1991-05-23 1992-11-25 Konica Corporation Silver halide color photographic light-sensitive material
JPH0649473A (ja) 1992-08-04 1994-02-22 Asahi Chem Ind Co Ltd 冷媒組成物
DE4323512A1 (de) 1992-09-01 1994-04-28 Agfa Gevaert Ag Fotografisches Aufzeichnungsmaterial
JPH09176240A (ja) * 1995-12-27 1997-07-08 Mitsubishi Chem Corp 光重合性組成物
JPH10133427A (ja) * 1996-11-05 1998-05-22 Fuji Xerox Co Ltd 静電潜像現像用キャリア、静電潜像現像剤及び画像形成方法
JPH10316803A (ja) 1997-05-16 1998-12-02 Teijin Chem Ltd 難燃性樹脂組成物
IL125840A (en) 1997-08-22 2002-12-01 Teijin Chemicals Ltd Bromine compound production method
JPH11166087A (ja) 1997-12-04 1999-06-22 Teijin Chem Ltd 難燃性樹脂組成物
AU4494399A (en) 1998-06-30 2000-01-24 University Of British Columbia, The Inhibitors of androgen-independent activation of androgen receptor
US6218430B1 (en) 1998-08-24 2001-04-17 Ligand Pharmaceuticals Incorporated Vitamin D3 mimics
JP3795679B2 (ja) 1998-09-01 2006-07-12 帝人化成株式会社 臭素化合物の製造方法
AU775928B2 (en) 1999-10-14 2004-08-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
US6534621B2 (en) 2000-05-18 2003-03-18 Dow Global Technologies Inc. Process for manufacturing a hydroxyester derivative intermediate and epoxy resins prepared therefrom
US6472436B1 (en) 2000-07-17 2002-10-29 The Salk Institute For Biological Studies Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
US6756400B2 (en) 2000-08-31 2004-06-29 Theravance, Inc. Sodium channel modulators
US6646102B2 (en) 2001-07-05 2003-11-11 Dow Global Technologies Inc. Process for manufacturing an alpha-dihydroxy derivative and epoxy resins prepared therefrom
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
CA2555597C (en) 2004-02-13 2016-06-14 The University Of British Columbia Radiolabeled compounds and compositions, their precursors and methods for their production
JP2006208607A (ja) 2005-01-26 2006-08-10 Fuji Photo Film Co Ltd パターン形成材料、並びにパターン形成装置及び永久パターン形成方法
JP4753601B2 (ja) 2005-03-23 2011-08-24 旭化成イーマテリアルズ株式会社 感光性組成物
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
JP2007290980A (ja) 2006-04-21 2007-11-08 Shin Etsu Chem Co Ltd 含フッ素（メタ）アクリル酸エステル
TW200819421A (en) 2006-10-31 2008-05-01 Univ Nat Chunghsing The method of synthesizing biphenol A, BPA having di-alkoxyl group by using polycarbonate or its waste
RU2572596C2 (ru) * 2008-07-02 2016-01-20 Бритиш Коламбиа Кэнсер Эйдженси Бранч Терапевтические средства на основе производных диглицилиловых простых эфиров и способы их применения
AR079846A1 (es) * 2010-01-06 2012-02-22 British Columbia Cancer Agency Agentes terapeuticos derivados de bisfenol que contienen un grupo aquiral y su uso en el tratamiento del cancer
AR079975A1 (es) 2010-01-06 2012-03-07 British Columbia Cancer Agency Agentes terapeuticos derivados de bisfenol u metodos para su uso, composiciones farmaceuticas y uso de los mismos
EP2693875A4 (en) 2011-04-08 2014-10-22 British Columbia Cancer Agency BISPHENOL COMPOUNDS AND METHOD FOR THEIR USE
WO2012145328A1 (en) 2011-04-18 2012-10-26 The University Of British Columbia Dibenzylphenyl compounds and methods for their use
WO2012145330A1 (en) 2011-04-18 2012-10-26 The University Of British Columbia Fluorene-9-bisphenol compounds and methods for their use
WO2013028572A1 (en) * 2011-08-19 2013-02-28 British Columbia Cancer Agency Branch Fluorinated bisphenol ether compounds and methods for their use
WO2013028791A1 (en) * 2011-08-22 2013-02-28 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
CN105358522A (zh) * 2013-05-10 2016-02-24 不列颠哥伦比亚癌症局分支机构 雄激素受体调节剂的酯衍生物及其使用方法
US20150010469A1 (en) 2013-07-03 2015-01-08 British Columbia Cancer Agency Branch Bisphenol ether compounds with novel bridging groups and methods for their use

Also Published As

Publication number Publication date
KR20170060162A (ko) 2017-05-31
CA2911352A1 (en) 2014-11-13
KR101739800B1 (ko) 2017-05-25
HK1221712A1 (zh) 2017-06-09
EP2994451A1 (en) 2016-03-16
AU2014262333B2 (en) 2016-06-16
AU2014262333A1 (en) 2015-11-19
SG11201509038UA (en) 2015-12-30
PE20160091A1 (es) 2016-03-03
US9173939B2 (en) 2015-11-03
JP2016518394A (ja) 2016-06-23
MX347705B (es) 2017-05-09
KR20160013072A (ko) 2016-02-03
US20140335080A1 (en) 2014-11-13
JP2017125036A (ja) 2017-07-20
SG10201607177XA (en) 2016-10-28
EP2994451A4 (en) 2016-10-05
IL242345A (en) 2017-02-28
PH12015502525A1 (en) 2016-03-28
US20160068466A1 (en) 2016-03-10
PH12016501047A1 (en) 2018-06-25
CL2015003271A1 (es) 2016-04-22
AP2015008838A0 (en) 2015-11-30
CN105358522A (zh) 2016-02-24
JP6100439B2 (ja) 2017-03-22
WO2014179867A1 (en) 2014-11-13
AU2016228233A1 (en) 2016-10-06
MX2015015509A (es) 2016-08-12

Similar Documents

Publication Publication Date Title
BR112015028174A2 (pt) composto, composição farmacêutica, uso de uma composição farmacêutica, e, métodos para modulação de atividade de receptores de andrógeno e para aumentar a biodisponibilidade de um modulador de receptor de andrógeno
CY1124810T1 (el) Συνδυαστικη θεραπεια για τη θεραπευτικη αντιμετωπιση του καρκινου
BR112015024530A8 (pt) compostos derivados de naftiridina úteis como antagonistas de integrina alfa-v-beta-6, composição farmacêutica, e, uso de um composto
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
BR112016000489A8 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
EA201591455A1 (ru) Производные бензимидазолона в качестве ингибиторов бромодомена
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112015028017A2 (pt) composto, composição farmacêutica, e, uso de um composto
EA201591537A1 (ru) Производные бензотиофена и композиции, их содержащие, в качестве селективных супрессоров эстрогеновых рецепторов
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
ECSP15035343A (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa pim
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
EA201692003A1 (ru) Макроциклические производные пиримидина
BR112015030399A2 (pt) derivados heterocíclicos e uso dos mesmos
MX383928B (es) Derivado de piridona que tiene un grupo tetrahidropiranilmetilo.
EA029499B9 (ru) Ингибиторы rorc2 и способы их применения
MX377267B (es) Tratamiento de cáncer con dihidropirazino-pirazinas.
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CU20110088A7 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]